CN107607721B - Chlorpromazine magnetic immunochemiluminescence detection kit and application thereof - Google Patents
Chlorpromazine magnetic immunochemiluminescence detection kit and application thereof Download PDFInfo
- Publication number
- CN107607721B CN107607721B CN201710835732.6A CN201710835732A CN107607721B CN 107607721 B CN107607721 B CN 107607721B CN 201710835732 A CN201710835732 A CN 201710835732A CN 107607721 B CN107607721 B CN 107607721B
- Authority
- CN
- China
- Prior art keywords
- chlorpromazine
- solution
- magnetic
- enzyme
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 title claims abstract description 85
- 229960001076 chlorpromazine Drugs 0.000 title claims abstract description 82
- 238000001514 detection method Methods 0.000 title abstract description 31
- 239000000427 antigen Substances 0.000 claims abstract description 33
- 102000036639 antigens Human genes 0.000 claims abstract description 33
- 108091007433 antigens Proteins 0.000 claims abstract description 33
- 102000004190 Enzymes Human genes 0.000 claims abstract description 31
- 108090000790 Enzymes Proteins 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000003085 diluting agent Substances 0.000 claims abstract description 21
- 239000000758 substrate Substances 0.000 claims abstract description 18
- 239000011324 bead Substances 0.000 claims abstract description 17
- 241001465754 Metazoa Species 0.000 claims abstract description 12
- 238000002038 chemiluminescence detection Methods 0.000 claims abstract description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 56
- 239000000523 sample Substances 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 238000004140 cleaning Methods 0.000 claims description 12
- 239000012224 working solution Substances 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 11
- 238000003860 storage Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 238000005259 measurement Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 238000007885 magnetic separation Methods 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 229940098773 bovine serum albumin Drugs 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 6
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 claims description 6
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- GWQSENYKCGJTRI-UHFFFAOYSA-N 1-chloro-4-iodobenzene Chemical compound ClC1=CC=C(I)C=C1 GWQSENYKCGJTRI-UHFFFAOYSA-N 0.000 claims description 3
- XQCWOAMYQRDOQY-UHFFFAOYSA-N 2-iodoacetaldehyde Chemical compound ICC=O XQCWOAMYQRDOQY-UHFFFAOYSA-N 0.000 claims description 3
- SKCBQZZEOBAUEM-UHFFFAOYSA-N 3-bromothiophen-2-ol Chemical compound OC=1SC=CC=1Br SKCBQZZEOBAUEM-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000012488 sample solution Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- LZBYGYFTQRAERK-UHFFFAOYSA-N 1-chloropiperazin-2-ol Chemical compound ClN1C(CNCC1)O LZBYGYFTQRAERK-UHFFFAOYSA-N 0.000 claims description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 claims description 2
- 239000012043 crude product Substances 0.000 claims description 2
- -1 hydroxyl chlorpromazine Chemical compound 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000001308 synthesis method Methods 0.000 claims 1
- 210000004080 milk Anatomy 0.000 abstract description 9
- 239000008267 milk Substances 0.000 abstract description 9
- 235000013336 milk Nutrition 0.000 abstract description 9
- 230000035945 sensitivity Effects 0.000 abstract description 9
- 238000005406 washing Methods 0.000 abstract description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 4
- 241000238557 Decapoda Species 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 235000015277 pork Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- HICFFJZGXWEIHN-UHFFFAOYSA-N 8-chloro-10-[3-(dimethylamino)propyl]-3-phenothiazinol Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=C(O)C=C3SC2=C1 HICFFJZGXWEIHN-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000013408 indirect enzyme-linked immunoassay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a chlorpromazine magnetic immune chemiluminescence detection kit, which comprises: the kit comprises an enzyme-labeled antigen, an enzyme-labeled antigen diluent, a magnetic-labeled antibody diluent, chlorpromazine series standard substance solutions, a chemiluminescent substrate A solution, a chemiluminescent substrate B solution, a complex solution and a washing solution, wherein the enzyme-labeled antigen is a chlorpromazine hapten marked by horseradish peroxidase, and the magnetic-labeled antibody is a chlorpromazine monoclonal antibody marked by immunomagnetic beads. The invention also discloses a method for detecting the chlorpromazine residual quantity in animal tissues and milk by using the kit matched with the chemiluminescence detector, and the method has higher sensitivity and specificity and shorter detection time for the chlorpromazine detection.
Description
Technical Field
The invention relates to a chemiluminescence detection kit and a detection method thereof, in particular to a magnetic immunity chemiluminescence detection kit for detecting chlorpromazine residual quantity in samples such as animal tissues, milk and the like, belonging to the field of immunological detection.
Background
Chlorpromazine (Chlorpromazine) is a phenothiazine drug, is a blocker of central dopamine receptors, acts on the central nervous system, and has various pharmacological effects such as antipsychotic, cooling, antiemetic, hypnotic, anesthesia and the like. Veterinary medicine is mainly used as sedative in clinical practice. In recent years, driven by benefits, chlorpromazine is added privately in feed and drinking water to achieve the effects of calming and hypnosis, so that the effects of fattening and promoting growth are indirectly achieved; or in the transportation process, in order to reduce weight loss and stress death in the way and prevent meat quality from decreasing, chlorpromazine is often used in large amount, and especially before slaughtering, the chlorpromazine is used in large amount, so that chlorpromazine can be left in livestock and poultry products.
Chlorpromazine is mainly metabolized by the liver in vivo and mostly eliminated from urine, but accumulation and residue in vivo are easy to generate due to slow excretion, and the residue can be remained in animal tissues for several months. The residual chlorpromazine in animal tissues enters human bodies through food chains, can cause leucopenia, agranulocytosis and other adverse reactions, and directly influences the physical health of people. Meanwhile, the product outlet is influenced due to the excessive residue, and huge economic loss is brought to the breeding industry. Therefore, the addition of chlorpromazine to feed (EC) No.17/97 was mandated by the European Union as early as 1997; the 176 th bulletin (2002) of department of agriculture in China also clearly indicates that: chlorpromazine is strictly prohibited to be added into animal feed and drinking water; ministry of agriculture publication No. 235 (2002) again states: the therapeutic effect of chlorpromazine is allowed but not detectable in animal products.
Driven by economic benefits, the phenomenon of illegal abuse of chlorpromazine is often prohibited, and the classical chromatographic method cannot meet the rapid detection requirement of a large number of samples on site, so that the appearance of portable and high-sensitivity rapid detection products is urgently needed. The immunoassay method is a rapid analysis method established by taking the specific reaction of an antigen and an antibody as a basic principle, and the technology is widely applied to the field of drug residue detection due to the high selectivity and sensitivity of the combination of the antigen and the antibody. Currently, the most commonly used immunodetection methods include enzyme-linked immunosorbent assay and colloidal gold immunochromatographic assay, but due to the low sensitivity and high false negative and false positive rates, the methods are gradually replaced by chemiluminescence immunodetection methods with high sensitivity, high accuracy and short detection time. The magnetic immunochemiluminescence detection reagent is matched with a magnetic immunochemiluminescence detector to detect the residual amount of the chlorpromazine in the animal-derived product, so that the full automation of the detection process is realized, the manual operation error is reduced, the sensitivity is high, the accuracy is high, the detection cost is low, and the magnetic immunochemiluminescence detection reagent is suitable for screening the residual amount of the chlorpromazine in a large batch of samples.
Disclosure of Invention
The invention aims to provide a chlorpromazine detection kit, which has higher sensitivity, specificity and accuracy when used for detecting the chlorpromazine residual quantity.
The invention also aims to provide a method for detecting chlorpromazine, which has higher sensitivity, specificity and accuracy when a chemiluminescence detector matched with the kit is used for detecting the residual amount of the chlorpromazine, realizes full-automatic detection, shortens the detection time and reduces the manual operation error.
The kit of the invention comprises: enzyme-labeled antigen, enzyme-labeled antigen diluent, magnetic-labeled antibody diluent, chlorpromazine series standard substance solution, chemiluminescence substrate A solution, chemiluminescence substrate B solution, complex solution and washing solution.
The enzyme-labeled antigen is a chlorpromazine hapten labeled by horse radish peroxidase, the magnetic labeled antibody is a chlorpromazine monoclonal antibody labeled by immunomagnetic beads, and the chlorpromazine monoclonal antibody is prepared by taking a conjugate obtained by coupling the chlorpromazine hapten and bovine serum albumin as an immunogen to immunize animals; the chlorpromazine hapten is obtained by reacting an N1- (5-chloro-2-iodobenzene) -N3 compound with 3-bromo-2-thiophenol to obtain an intermediate hydroxy chlorpromazine and then reacting the intermediate hydroxy chlorpromazine with iodoacetaldehyde, and the molecular structural formula of the chlorpromazine hapten is as follows:
the surface of the immunomagnetic bead contains-OH, -COOH or-NH2An active group.
The chemiluminescence substrate A solution is a trihydroxymethyl aminomethane solution containing luminol and p-cresol, and the chemiluminescence substrate B solution is a trihydroxymethyl aminomethane solution containing citric acid and anhydrous Na2HPO4And CO (NH)2)2·H2O2An aqueous solution of (a).
The concentration of the chlorpromazine series standard solution is 0 mug/L, 0.05 mug/L, 0.15 mug/L, 0.45 mug/L, 1.35 mug/L and 4.05 mug/L respectively.
The enzyme-labeled antigen diluent is Na with pH of 7.2-7.63PO4Concentration of 0.01mol/L, NaCl concentration of 0.25mol/L of buffer solution.
The magnetic labeling antibody diluent is Na with pH of 7.2-7.63PO4The concentration of the buffer solution is 0.01mol/L, NaCl and the concentration of the buffer solution is 0.25 mol/L.
The double solution is phosphate buffer solution with pH 7.0 and 0.1 mol/L.
The washing solution is pH7.4, and contains 0.5-1.0% of Tween-20, 0.01-0.03% of sodium azide and 0.1-0.3 mol/L of phosphate buffer solution.
The kit is matched with a chemiluminescence detector to detect the residual amount of chlorpromazine in animal tissues and milk samples.
The invention also provides a method for detecting the residual amount of chlorpromazine by using the chemiluminescence detector matched with the kit, which comprises the following steps:
1) diluting an enzyme-labeled antigen and an enzyme-labeled antigen diluent according to a volume ratio of 1: 10-1: 20, and filling the diluted enzyme-labeled antigen and the enzyme-labeled antigen diluent into a chemiluminescence detector enzyme-labeled antigen working solution container;
2) diluting a magnetic standard antibody and a magnetic standard antibody diluent according to a volume ratio of 1: 10-1: 20, and putting the diluted magnetic standard antibody and the magnetic standard antibody diluent into a chemiluminescence detector magnetic standard antibody working solution container;
3) respectively absorbing 30-60 mu L of enzyme-labeled antigen working solution, 30-60 mu L of sample solution to be detected and 30-60 mu L of magnetic label antibody working solution by a chemiluminescence detector, sequentially adding the solutions into a reaction cup storage device, reacting for 15min at room temperature, carrying out magnetic separation for 2-4 min by a cleaning device, removing supernatant, and cleaning the compound precipitate for 3-5 times by 300-500 mu L of cleaning solution;
4) and (3) putting the separated compound into a measurement dark box, adding 50 mu L of each of the chemiluminescence substrate A liquid and the chemiluminescence substrate B liquid, detecting the emitted relative light intensity, enabling the content of the chlorpromazine in the sample to have a negative correlation with the relative light intensity, and calculating the residual amount of the chlorpromazine through a relative light intensity standard curve.
The chemiluminescence detector used in the analysis and test method comprises a power supply circuit, a reaction cup storage device, a sample arm, a reagent storage device, a reagent arm, a movable refrigeration device, a cleaning device, an automatic injection pump, a low-light-level detector, and Windows control software with a computer and a Chinese interface, can perform functions of data entry, result summarization, quality control, result storage, result query and the like, can complete programming of various analysis modes, report results quantitatively or qualitatively, automatically generate, store and update functions, and automatically correct standard curves at two points.
The invention has the following beneficial effects:
1) the kit has higher sensitivity and specificity, and the detection sensitivity of the kit on the chlorpromazine can reach 0.05 mu g/L.
2) The kit provided by the invention is matched with a chemiluminescence detector to detect the residual amount of chlorpromazine in a sample, so that the full automation of the detection process is realized, the manual operation error is reduced, the detection time is short, and the detection of the residual amount of chlorpromazine in the sample can be completed in only 20 min.
Drawings
FIG. 1: chlorpromazine hapten synthesis scheme
FIG. 2: standard curve diagram of magnetic immune chemiluminescence detection kit
Detailed Description
The invention is further illustrated below with reference to specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Example 1: preparation of concrete components of chlorpromazine magnetic immune chemiluminescence detection kit
1. Synthesis and identification of chlorpromazine hapten (the synthetic route is shown in figure 1)
A.1.0g of N1- (5-chloro-2-iodobenzene) -N3 compound is dissolved in anhydrous N, N-Dimethylformamide (DMF), 0.8g of cuprous iodide is added, 0.3g of sodium hydride is added, 0.66g of 3-bromo-2-thiophenol is added, the mixture is heated in an oil bath, the reaction is stopped for 4 hours at 100 ℃, the mixture is cooled to room temperature, water is added, ethyl acetate is added for extraction, rotary evaporation is carried out and evaporation is carried out to dryness, the mixture is applied to a silica gel column, and petroleum ether/ethyl acetate (v/v, 10/1) is eluted and separated to obtain 0.9g of intermediate hydroxychloropiperazine, and the yield is 91.84%;
B. taking 0.9g of hydroxyl chlorpromazine, adding acetonitrile for dissolving and clarifying, adding 0.54g of iodoacetaldehyde and 0.43g of potassium carbonate, stirring for 3 hours at 50 ℃, stopping reaction, adding water, extracting with ethyl acetate, evaporating to dryness to obtain a crude product, and recrystallizing with dichloromethane/n-hexane (v/v, 1/1) to obtain 0.98g of acetaldehyde chlorpromazine hapten product, wherein the yield is 96.74%.
Taking the hapten, performing nuclear magnetic resonance hydrogen spectrum identification,1H-NMR(CDCl3,300MHz)：9.71(1H,s,CHO)，7.10(2H,dd,ArH)，6.76(2H,dd,ArH)，6.26(1H,dd,ArH)，5.50(2H,dd,CH2)，3.93(2H,dd,CH2)，2.46(2H,dd,CH2)，2.26(2H,s,CH3)，1.67(2H,dd,CH2). Wherein, the chemical shift is 9.71 and 5.50 are resonance absorption peaks of aldehyde group hydrogen on the spacer arm, and the existence of the peaks proves the success of hapten synthesis.
2. Preparation of enzyme-labeled antigen
Taking 14mg of chlorpromazine hapten, adding 0.3mL of ethanol for dissolving and clarifying to obtain solution A; dissolving horseradish peroxidase (HRP)50mg in 0.1mol/L carbonate buffer solution to obtain solution B; dripping the A solution into the B solution, stirring overnight at 4 ℃, dialyzing and purifying 0.02mol/L PB for three days, changing the solution three times per day to obtain the enzyme-labeled antigen, and subpackaging and storing at-20 ℃.
3. Preparation of immunogens
HRP is replaced by Bovine Serum Albumin (BSA), and the preparation method is the same as the above, so that the immunogen is obtained.
4. Preparation of chlorpromazine monoclonal antibody
(1) Obtaining hybridoma cells
1) First immunization: chlorpromazine hapten-BSA conjugate (immunogen) and an equal amount of Freund's complete adjuvant are fully emulsified, and 6-week-old Balb/c mice are injected subcutaneously, wherein each mouse is 0.2 mL;
2) two booster immunizations: from the first immunization, boosting once every two weeks, and replacing Freund's complete adjuvant with Freund's incomplete adjuvant in the same method and dosage as the first immunization;
3) after one week of last boosting immunization, measuring the titer and inhibition in fundus venous blood sampling, and performing the following last immunization when the titer reaches more than 1: 10000: injecting 0.1mL of immunogen solution without any adjuvant into the abdominal cavity, killing the mouse after three days, and fusing the spleen with myeloma cells;
4) and (4) measuring cell supernatant by adopting an indirect enzyme-linked immunoassay method, and screening positive holes. Cloning the positive hole by using a limiting dilution method to obtain and establish a hybridoma cell strain which stably secretes the chlorpromazine monoclonal antibody, preparing the hybridoma cell in a logarithmic growth phase into a cell suspension by using a freezing medium, subpackaging in a freezing tube, and storing in liquid nitrogen for a long time.
(2) Preparation of monoclonal antibodies
1) Cell recovery: taking out the cryopreserving tube of the chlorpromazine monoclonal antibody hybridoma cell strain, immediately putting the cryopreserving tube into a water bath at 37 ℃ for medium-speed melting, centrifugally removing a cryopreserving liquid, and transferring the cryopreserving liquid into a culture bottle for culture;
2) preparing ascites and purifying antibody by injecting 0.5mL of sterilized paraffin oil into the abdominal cavity of Balb/c mouse (8 weeks old) by in vivo induction method, and injecting hybridoma cells 5 × 10 into the abdominal cavity after 7 days5Ascites were collected 7 days later. Purifying by octanoic acid-saturated ammonium sulfate method, determining purity by SDS-PAGE electrophoresis, subpackaging with small bottles, and storing at-20 deg.C.
5. Preparation of magnetic labeled antibody
The process takes carboxyl magnetic beads with the particle size of 2.8 mu m as a carrier, the tail ends of the carboxyl magnetic beads have reactive carboxyl groups, and after the carboxyl magnetic beads are combined and treated by an activating agent EDC-NHS, the activated magnetic beads can be coupled with a chlorpromazine monoclonal antibody, and the specific steps are as follows:
(1) cleaning: 100 μ L of carboxyl magnetic beads (purchased from DYNAL, particle size of 2.8 μm, content of 0.15eq/g) were placed in a centrifuge tube, washed 2 times with 100 μ L of MES solution containing 0.05% Tween-20, pH5.0, 25mmol/L, and the supernatant was removed after magnetic separation;
(2) and (3) activation: respectively preparing 50mmol/L EDC solution and NHS solution by using 25mmol/L MES solution with pH value of 5.0 stored at 4 ℃; respectively adding 50 μ L of newly prepared EDC and NHS solution into a centrifuge tube filled with magnetic beads, mixing uniformly by vortex, activating at room temperature for 30min, removing supernatant after magnetic separation, and washing with (1) MES solution for 2-3 times;
(3) coupling: dissolving chlorpromazine monoclonal antibody into 60 mu L of MES solution with pH of 5.0 and 25mmol/L, adjusting the total volume to 100 mu L with the MES solution, gently adding the solution into activated magnetic beads, and coupling at room temperature for 30min or 4 ℃ for 2h, wherein the magnetic beads are kept in a uniform mixing state;
(4) and (3) sealing: removing supernatant after magnetic separation, adding 100 μ L TRIS solution with pH of 7.4, reacting for 15min, and sealing magnetic beads;
(5) and (3) storage: removing supernatant after magnetic separation, washing the sealed magnetic beads with 100 μ L TRIS solution containing 0.1% -0.3% BSA and 0.1% Tween-20 for 3-5 times, removing supernatant after magnetic separation, and re-dissolving the magnetic beads in a solution containing 0.1% -0.5% BSA, 0.01% -0.1% Tween-20, and 0.02% NaN3The TRIS solution (concentration: 10mg/mL) was stored at 2-8 ℃ until use.
Example 2: construction of chlorpromazine magnetic immunity chemiluminescence detection kit
The chlorpromazine magnetic immunochemiluminescence detection kit is constructed and comprises the following components:
(1) horseradish peroxidase-labeled chlorpromazine hapten;
(2) the enzyme-labeled antigen diluent is pH 7.2-7.6 and Na3PO4A buffer solution with the concentration of 0.01mol/L, NaCl and the concentration of 0.25 mol/L;
(3) chlorpromazine monoclonal antibody marked by immunomagnetic beads;
(4) the dilution liquid of the magnetic labeled antibody is pH 7.2-7.6 and Na3PO4A buffer solution with the concentration of 0.01mol/L, NaCl and the concentration of 0.25 mol/L;
(5) the concentration of the chlorpromazine series standard solution is 0 mug/L, 0.05 mug/L, 0.15 mug/L, 0.45 mug/L, 1.35 mug/L and 4.05 mug/L respectively;
(6) the chemiluminescence substrate A solution is a trihydroxymethyl aminomethane solution containing luminol and p-cresol, and the chemiluminescence substrate B solution is a trihydroxymethyl aminomethane solution containing citric acid and anhydrous Na2HPO4And CO (NH)2)2·H2O2An aqueous solution of (a);
(7) the compound solution is phosphate buffer solution with pH 7.0 and 0.1 mol/L;
(8) the washing solution is pH7.4, and contains 0.5-1.0% of Tween-20, 0.01-0.03% of sodium azide and 0.1-0.3 mol/L of phosphate buffer solution.
Example 3: detection of chlorpromazine residual quantity in sample
1. Sample pretreatment
(1) Animal tissue (chicken, pork, fish, shrimp) samples: weighing 2.0g + -0.05 g homogenized tissue sample into a 50mL polystyrene centrifuge tube, adding 2mL 2.5% trichloroacetic acid and 6mL acetone respectively, shaking for 5min with a shaker, mixing, and centrifuging at 3000g room temperature (20-25 deg.C/68-77 ℉) for 5 min; transferring 2mL of the supernatant into a 50mL polystyrene centrifuge tube, adding 2mL of 2mol/L sodium hydroxide solution and 4.5mL of n-hexane respectively, shaking for 5min with a shaker, mixing, and centrifuging at 3000g room temperature (20-25 deg.C/68-77 ℉) for 5 min; transferring 3mL of the upper organic phase into a 10mL clean dry glass tube, and drying the upper organic phase in a water bath nitrogen flow at 50-60 ℃ (122-; adding 0.5mL of the complex solution, and vortexing for 2min by using a vortex instrument to dissolve the dried residue; 50 μ L was taken for analysis.
(2) Milk sample: transferring 1mL fresh milk sample into a 50mL polystyrene centrifuge tube, adding 1mL 10% trichloroacetic acid, vortexing for 2min with a vortex instrument, adding 6mL acetone, vigorously shaking for 5min with a shaker, mixing, and centrifuging for 5min at 3000g room temperature (20-25 deg.C/68-77 deg.F); transferring 2mL of the supernatant into a 50mL polystyrene centrifuge tube, adding 2mL of 2mol/L sodium hydroxide solution and 4.5mL of n-hexane respectively, shaking for 5min with a shaker, mixing, and centrifuging at 3000g room temperature (20-25 deg.C/68-77 ℉) for 5 min; transferring 3mL of the upper organic phase into a 10mL clean dry glass tube, and drying the upper organic phase in a water bath nitrogen flow at 50-60 ℃ (122-; adding 0.5mL of the complex solution, and vortexing for 2min by using a vortex instrument to dissolve the dried residue; 50 μ L was taken for analysis.
2. Detection with a kit
Diluting an enzyme-labeled antigen and an enzyme-labeled antigen diluent according to a volume ratio of 1: 10-1: 20, and filling the diluted enzyme-labeled antigen and the enzyme-labeled antigen diluent into a chemiluminescence detector enzyme-labeled antigen working solution container; diluting a magnetic standard antibody and a magnetic standard antibody diluent according to a volume ratio of 1: 10-1: 20, and putting the diluted magnetic standard antibody and the magnetic standard antibody diluent into a chemiluminescence detector magnetic standard antibody working solution container; setting the position on a sample rack for each sample/standard product, and inputting sample information and a test project name to be detected; putting the sample tube/standard sample tube on a set sample frame, sequentially sucking 50 mu L of enzyme-labeled antigen working solution, 50 mu L of sample/standard product to be detected and 50 mu L of magnetic standard antibody working solution by a chemiluminescence detector, adding the mixture into a reaction cup storage device, uniformly mixing, reacting for 15min at room temperature, carrying out magnetic separation for 4min by a cleaning device, removing supernatant, cleaning the precipitate of the compound by using a cleaning solution for 3-5 times, adding 50 mu L of each of a chemiluminescence substrate A solution and a chemiluminescence substrate B solution, detecting relative light intensity (RLU) emitted by the mixture, enabling the content of chlorpromazine in the sample to be in a negative correlation with the RLU, and calculating the residual amount of chlorpromazine by combining the RLU with a standard curve method.
3. Analysis of detection results
Dividing the RLU mean (RLU) of the standard solutions obtained for each concentration by the RLU value (RLU) of the first standard solution (0 standard)0) And multiplied by 100% to obtain the relative luminescence intensity (%). A standard curve is drawn by taking the logarithmic value of the chlorpromazine standard substance concentration (μ g/L) as the abscissa and the relative luminous intensity as the ordinate, as shown in FIG. 2. The relative luminous intensity of the sample solution is calculated by the same method, and the chlorpromazine content corresponding to each sample can be read from the standard curve.
Example 4: quality evaluation of chlorpromazine magnetic immune chemiluminescence detection kit
1. Detection limit
The detection is carried out on 20 parts of blank pork, chicken, fish, shrimp and milk samples respectively, the concentration corresponding to each relative luminous intensity is found out from the standard curve, the average value of the 20 parts of sample concentration is added with 3 times of standard deviation to represent the detection limit, and as a result, the detection limit of the method on animal tissue samples is 0.1 mug/kg, and the detection limit on milk samples is 0.2 mug/L.
2. Sample precision and accuracy testing
The recovery rate is used as an accuracy evaluation index, and the relative standard deviation (RSD%) of the detection result of a sample with a certain concentration is repeatedly measured and used as a precision evaluation index. The calculation formula is as follows: recovery (%) — actual measurement/theoretical value × 100%, where theoretical value is the added concentration of the sample; relative standard deviation RSD% ═ SD/X × 100%, where SD is the standard deviation and X is the average of the measured data.
The method comprises the steps of performing addition recovery measurement on blank pork, chicken, fish and shrimp samples according to three chlorpromazine concentrations of 0.1 mu g/kg, 0.2 mu g/kg and 0.4 mu g/kg, performing addition recovery measurement on the blank milk samples according to three chlorpromazine concentrations of 0.2 mu g/L, 0.4 mu g/L and 0.8 mu g/L, performing 4 parallel measurement on each sample, performing measurement by using three different kits, and calculating the average recovery rate and precision of the samples, wherein the results are shown in Table 1.
TABLE 1 precision and accuracy tests
Adding chlorpromazine with three concentrations of 0.1, 0.2 and 0.4 mu g/kg to blank pork, chicken, fish and shrimp samples, and adding chlorpromazine with three concentrations of 0.2, 0.4 and 0.8 mu g/L to blank milk samples, wherein the average recovery rate is 70-110%; the relative standard deviation in each batch and between batches is less than 10 percent.
3. Specificity test
The drugs with similar structures and functions to chlorpromazine are selected for determination, the 50% inhibition concentration of each drug is obtained through a standard curve of each drug, the cross reaction rate of the kit to other drugs is calculated by the following formula, and the result is shown in table 2.
TABLE 2 Cross-reactivity test
| Name of drug | IC50 | Cross-reactivity (%) |
| Chlorpromazine | 0.145 | 100 |
| Promethazine | — | ＜1 |
| Acetylpromazine maleic acid | — | ＜1 |
Note: IC (integrated circuit)50Is "-" because the curve is distorted and deformed, it cannot be used to calculate a specific value.
4. Stability test
The storage condition of the kit is 2-8 ℃, and the maximum RLU value (zero standard), the 50% inhibition concentration and the actual measurement value of chlorpromazine addition of the kit are within the normal range after 12 months of measurement. Considering that abnormal storage conditions occur in the transportation and use processes, the kit is placed for 7 days under the storage condition of 37 ℃ for accelerated aging experiments, and the results show that all indexes of the kit completely meet the requirements. And in consideration of the occurrence of the freezing condition of the kit, the kit is frozen for 7 days in a refrigerator at the temperature of-20 ℃, and the determination result also shows that all indexes of the kit are completely normal. From the above results, it can be obtained that the kit can be stored at 2 to 8 ℃ for at least 12 months.
Claims (5)
1. A chlorpromazine magnetic immune chemiluminescence detection kit comprises an enzyme-labeled antigen, an enzyme-labeled antigen diluent, a magnetic-labeled antibody diluent, chlorpromazine series standard substance solutions, a chemiluminescence substrate A solution, a chemiluminescence substrate B solution, a complex solution and a cleaning solution; the method is characterized in that: the enzyme-labeled antigen is a chlorpromazine hapten labeled by horse radish peroxidase, the magnetic labeled antibody is a chlorpromazine monoclonal antibody labeled by immunomagnetic beads, and the chlorpromazine monoclonal antibody is prepared by taking a conjugate obtained by coupling the chlorpromazine hapten and bovine serum albumin as an immunogen to immunize animals; the synthesis method of the chlorpromazine hapten comprises the following steps: dissolving 1.0g of N1- (5-chloro-2-iodobenzene) -N3 compound in anhydrous N, N-dimethylformamide, adding 0.8g of cuprous iodide, 0.3g of sodium hydride and 0.66g of 3-bromo-2-thiophenol, heating in an oil bath, reacting at 100 ℃ for 4 hours, stopping reaction, cooling to room temperature, adding water, extracting with ethyl acetate, evaporating to dryness, loading on a silica gel column, eluting with petroleum ether/ethyl acetate in a volume ratio of 10:1, and separating to obtain an intermediate, namely, hydroxychloropiperazine 0.9; taking 0.9g of hydroxyl chlorpromazine, adding acetonitrile for dissolving and clarifying, adding 0.54g of iodoacetaldehyde and 0.43g of potassium carbonate, stirring for 3 hours at 50 ℃, stopping reaction, adding water, extracting with ethyl acetate, evaporating to dryness to obtain a crude product, and recrystallizing with dichloromethane/n-hexane at a volume ratio of 1:1 to obtain 0.98g of an acetaldehyde chlorpromazine hapten, namely a chlorpromazine hapten, wherein the molecular structural formula of the acetaldehyde chlorpromazine hapten is as follows:
2. the kit of claim 1, wherein: the surface of the immunomagnetic bead contains-OH, -COOH or-NH2An active group.
3. The kit of claim 1, wherein: the chemiluminescence substrate A solution is a trihydroxymethyl aminomethane solution containing luminol and p-cresol, and the chemiluminescence substrate B solution is a trihydroxymethyl aminomethane solution containing citric acid and anhydrous Na2HPO4And CO (NH)2)2·H2O2An aqueous solution of (a).
4. The kit of claim 1, wherein: the kit is matched with a chemiluminescence detector to detect the residual amount of chlorpromazine.
5. A method for detecting chlorpromazine by using the kit of any one of claims 1 to 4, comprising the steps of:
1) diluting an enzyme-labeled antigen and an enzyme-labeled antigen diluent according to a volume ratio of 1: 10-1: 20, and filling the diluted enzyme-labeled antigen and the enzyme-labeled antigen diluent into a chemiluminescence detector enzyme-labeled antigen working solution container;
2) diluting a magnetic standard antibody and a magnetic standard antibody diluent according to a volume ratio of 1: 10-1: 20, and putting the diluted magnetic standard antibody and the magnetic standard antibody diluent into a chemiluminescence detector magnetic standard antibody working solution container;
3) respectively absorbing 30-60 mu L of enzyme-labeled antigen working solution, 30-60 mu L of sample solution to be detected and 30-60 mu L of magnetic label antibody working solution by a chemiluminescence detector, sequentially adding the solutions into a reaction cup storage device, reacting for 15min at room temperature, carrying out magnetic separation for 2-4 min by a cleaning device, removing supernatant, and cleaning the compound precipitate for 3-5 times by 300-500 mu L of cleaning solution;
4) and (3) putting the separated compound into a measurement dark box, adding 50 mu L of each of the chemiluminescence substrate A liquid and the chemiluminescence substrate B liquid, detecting the emitted relative light intensity, enabling the content of the chlorpromazine in the sample to have a negative correlation with the relative light intensity, and calculating the residual amount of the chlorpromazine through a relative light intensity standard curve.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710835732.6A CN107607721B (en) | 2017-09-16 | 2017-09-16 | Chlorpromazine magnetic immunochemiluminescence detection kit and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710835732.6A CN107607721B (en) | 2017-09-16 | 2017-09-16 | Chlorpromazine magnetic immunochemiluminescence detection kit and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107607721A CN107607721A (en) | 2018-01-19 |
| CN107607721B true CN107607721B (en) | 2020-08-28 |
Family
ID=61060211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710835732.6A Active CN107607721B (en) | 2017-09-16 | 2017-09-16 | Chlorpromazine magnetic immunochemiluminescence detection kit and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107607721B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3976763A (en) * | 1975-04-30 | 1976-08-24 | Hoffmann-La Roche Inc. | Chlorpromazine assay |
| CN101358967A (en) * | 2008-08-22 | 2009-02-04 | 北京望尔康泰生物技术有限公司 | Method for detecting chlorpromazine and special ELISA kit thereof |
| CN101553731A (en) * | 2006-08-22 | 2009-10-07 | 阿维科公司 | Active carrier, its production and its use |
| CN101987836A (en) * | 2010-08-31 | 2011-03-23 | 华南农业大学 | Chlorpromazine hapten, artificial antigen, antibody as well as preparation method and application thereof |
| CN102928402A (en) * | 2011-08-09 | 2013-02-13 | 北京勤邦生物技术有限公司 | Magnetic particle chemiluminescence kit for detecting chlorpromazine, and applications thereof |
| CN104897895A (en) * | 2015-04-14 | 2015-09-09 | 北京勤邦生物技术有限公司 | Gentamycin magnetic immunochemiluminescence detection kit and application thereof |
-
2017
- 2017-09-16 CN CN201710835732.6A patent/CN107607721B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3976763A (en) * | 1975-04-30 | 1976-08-24 | Hoffmann-La Roche Inc. | Chlorpromazine assay |
| CN101553731A (en) * | 2006-08-22 | 2009-10-07 | 阿维科公司 | Active carrier, its production and its use |
| CN101358967A (en) * | 2008-08-22 | 2009-02-04 | 北京望尔康泰生物技术有限公司 | Method for detecting chlorpromazine and special ELISA kit thereof |
| CN101987836A (en) * | 2010-08-31 | 2011-03-23 | 华南农业大学 | Chlorpromazine hapten, artificial antigen, antibody as well as preparation method and application thereof |
| CN102928402A (en) * | 2011-08-09 | 2013-02-13 | 北京勤邦生物技术有限公司 | Magnetic particle chemiluminescence kit for detecting chlorpromazine, and applications thereof |
| CN104897895A (en) * | 2015-04-14 | 2015-09-09 | 北京勤邦生物技术有限公司 | Gentamycin magnetic immunochemiluminescence detection kit and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107607721A (en) | 2018-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107907687A (en) | A kind of dicofol haptens preparation method and applications | |
| CN109374907B (en) | Colistin colloidal gold detection kit and application thereof | |
| CN101799472A (en) | Diethylstilbestrol detection kit and detection method | |
| CN101046474A (en) | Enzyme-linked immunological kit for detecting quinoxaline medicine residue | |
| CN102967709A (en) | Enzyme linked immunosorbent assay kit for detecting zearalenone drug and application thereof | |
| CN107271665B (en) | Test strip for detecting salbutamol and application thereof | |
| CN110133306B (en) | Enzyme linked immunosorbent assay kit for detecting cimaterol and application thereof | |
| CN102928417A (en) | Magnetic particle chemiluminescence kit for detecting sulfanilamide drugs, and applications thereof | |
| CN108254365B (en) | A kind of the magnetic immunochemiluminescence detection kit and its application of progesterone | |
| CN112067811B (en) | Test strip for detecting alternaria alternate and application thereof | |
| CN107607721B (en) | Chlorpromazine magnetic immunochemiluminescence detection kit and application thereof | |
| CN106645764B (en) | Detect enzyme linked immunological kit and its application of diazepam | |
| CN102928407A (en) | Magnetic particle chemiluminescence kit for detecting avermectins, and applications thereof | |
| CN117233374A (en) | Test strip for detecting meloxicam and application thereof | |
| CN108362891B (en) | Prednisone magnetic immuno-chemiluminescence detection kit and application thereof | |
| CN113603767B (en) | Talarmycin hapten, antibody and test strip thereof | |
| CN108051583A (en) | A kind of isazofos haptens preparation method and applications | |
| CN107643407B (en) | Trenbolone magnetic immunochemiluminescence detection kit and application thereof | |
| CN108717121A (en) | Test strips and method a kind of while that detect tetracycline medication, fluoroquinolones and sulfa drugs | |
| CN109971727B (en) | Hybridoma cell strain secreting monoclonal antibody against chloramphenicol and application thereof | |
| CN108362896B (en) | Magnetic immunochemiluminescence detection kit for apramycin and application thereof | |
| CN1707265A (en) | An enzyme-linked immunosorbent assay kit for detecting tetracycline drugs | |
| CN111751535A (en) | Test strip for detecting endosulfan and application thereof | |
| CN114019166A (en) | Test strip for detecting solanine and application thereof | |
| CN102539413A (en) | Magnetic particle chemiluminescence kit for detecting frazolidone metabolites and application of magnetic particle chemiluminescence kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |